StockData
Autolus Therapeutics plc logo

Autolus Therapeutics plc (AUTL) shareholders

AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3020% below fair value
$1.09−0.05 (-4.39%)

Close on Nov 17, 2026Market cap $290.12MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
49.7%
132M of 266M shares
Institutional holders
84
10 new, 10 sold out
Net institutional buying
-2M
In Q2 2026
Insider trades, 12 months
0 buys · 1 sales
Net sold $15.71K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
MAK Capital Fund LP
Joint filing with Mak Capital One LLC (12.60%), Kaufman Michael A (12.60%)
33,621,48712.60%13G (passive) amendmentMar 31, 2026
Roel Bulthuis
Joint filing with Syncona Portfolio Limited (10.80%), Syncona Holdings Limited (10.80%) and 4 more
28,821,05310.80%13G (passive) amendmentMar 31, 2025
Michael A. Kaufman
Joint filing with MAK Capital Fund LP (10.10%), MAK Capital One L.L.C. (10.10%)
26,887,50810.10%13G (passive) amendmentDec 1, 2025
Blackstone Inc.
Joint filing with BXLS V - Autobahn L.P. (7.60%), Blackstone Life Sciences Associates V (CYM) L.L.C. (7.60%) and 5 more
20,485,6117.60%13D (active) amendmentNov 6, 2026
Armistice Capital, LLC
Joint filing with Steven Boyd (5.94%)
15,800,0005.94%13G (passive) amendmentMar 31, 2026
MAK Capital One L.L.C.
Joint filing with MAK Capital Fund LP (5.80%), Michael A. Kaufman (5.80%)
15,408,6385.80%13G (passive)Jun 17, 2025
Steven Boyd
Joint filing with Armistice Capital, LLC (5.64%)
15,000,0005.64%13G (passive) amendmentJun 30, 2026
PPF Group a.s.
Joint filing with Renata Kellnerova (5.60%), AMALAR HOLDING s.r.o. (5.60%) and 1 more
14,782,2755.60%13D (active) amendmentAug 27, 2026
Ppf Biotech B.V.
Joint filing with Renata Kellnerova (5.50%), Ppf Group N.V. (5.50%)
14,612,2755.50%13D (active) amendmentMar 21, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of AUTLValueChange% of portfolio
Mak Capital One LLC33,621,48712.63%$53.79M–7.54%
Blackstone Inc.20,485,6117.70%$32.78M–0.10%
Syncona Portfolio Ltd16,640,7206.25%$26.63M–100.00%
Armistice Capital, LLC15,000,0005.64%$24.00M−800,0000.29%
TFG Asset Management GP Ltd9,500,0003.57%$15.20M–2.39%
Schroder Investment Management Group7,833,2822.94%$12.92M−1,656,0630.01%
Frazier Life Sciences Management, L.P.4,447,9101.67%$7.12M–0.15%
BNP PARIBAS ASSET MANAGEMENT Holding S.A.3,361,1561.26%$5.38M–0.01%
Laurion Capital Management LP3,316,6261.25%$5.31M–0.14%
Renaissance Technologies LLC1,984,7000.75%$3.18M−314,7990.00%
Bank Of America Corp /De/1,605,0920.60%$2.57M−239,5790.00%
BlackRock, Inc.1,603,4580.60%$2.57M+122,7260.00%
UBS Group AG1,516,9910.57%$2.43M+211,2120.00%
Morgan Stanley1,260,8320.47%$2.02M+319,0090.00%
Millennium Management LLC1,224,8180.46%$1.96M+1,020,0900.00%
Cetera Investment Advisers1,157,3240.43%$1.85M+28,2500.00%
Balyasny Asset Management L.P.972,7480.37%$1.56M+1,0570.00%
JPMorgan Chase & Co913,2390.34%$1.51M−22,1640.00%
Alphabet Inc.698,2620.26%$1.12M–0.00%
Citadel Advisors LLC695,8900.26%$1.11M+236,4860.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202684132M49.7%10 / 2821 / 103M5M
Q1 202684134M50.5%9 / 2230 / 136M11M
Q4 202589139M52.4%14 / 2529 / 1913M16M
Q3 202596146M54.7%14 / 3523 / 1238M58M
Q2 202594166M62.4%19 / 3326 / 2024M26M
Q1 202595168M63.2%8 / 3033 / 2313M14M
Q4 2024110168M63.3%23 / 3431 / 1413M24M
Q3 2024101180M67.6%7 / 3136 / 1620M14M
Q2 2024111179M67.1%15 / 3931 / 2429M27M
Q1 2024120177M66.6%27 / 4627 / 671M9M
Q4 202399116M43.6%34 / 2119 / 520M15M
Q3 202371111M41.6%10 / 1425 / 88M6M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

8 funds held AUTL in Q2 2026, 92% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of AUTLValue% of fundAs of
iShares Biotechnology ETF1,428,9290.54%$2.29M0.03%Jun 30, 2026
Fidelity Nasdaq Composite Index Fund120,8780.05%$226.04K0.00%May 31, 2026
State Street(R) SPDR(R) S&P(R) International Small Cap ETF84,4090.03%$135.05K0.02%Jun 30, 2026
Invesco NASDAQ Future Gen 200 ETF44,9360.02%$84.03K0.44%May 31, 2026
ActivePassive International Equity ETF22,7530.01%$42.55K0.00%May 31, 2026
Invesco Nasdaq Biotechnology ETF10,5750.00%$19.78K0.03%May 31, 2026
ProShares Ultra Nasdaq Biotechnology7,4140.00%$13.86K0.02%May 31, 2026
Blackstone Alternative Multi-Strategy Fund-14,000-0.01%-$22.40K-0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Christian ItinChief Executive Officer, Director1,116,0090.42%Mar 18, 2026
Cintia PiccinaU.S. CCO & Country Gen Manager13,2870.00%Sep 3, 2026
Christopher Andrew VannChief Operating Officer152,2110.06%Mar 18, 2026
Alexander SwanChief Human Resources Officer––Mar 18, 2026
Alex DriggsSVP, Legal Affairs and GC––Mar 18, 2026
Miranda Suzette NevilleChief Technology Officer––Mar 18, 2026
Robert DolskiChief Financial Officer––Mar 18, 2026
Patrick Paul McIlvennySVP Finance––Mar 18, 2026
Christopher Michael James WilliamsChief Business Officer8,1980.00%Mar 18, 2026
Matthias WillChief Development Officer––Mar 18, 2026
Linda BainDirector––Jul 1, 2026
Cynthia M. ButittaDirector––Jul 1, 2026
Ryan RichardsonDirector––Jul 1, 2026
Robert AzelbyDirector––Jul 1, 2026
Robert IannoneDirector––Jul 1, 2026
Elisabeth LeidermanDirector––Jul 1, 2026
Michael W. BonneyDirector––Jul 1, 2026
Madduri Ravin RaoDirector––Jul 1, 2026
William D. YoungDirector––Jul 1, 2026
John E. BerrimanDirector136,3310.05%Mar 18, 2026
Martin Anton PuleDirector––Mar 18, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Cintia Piccina
U.S. CCO & Country Gen Manager
Sep 2, 2026Sale−6,713$2.34$15.71K13,287
Cintia Piccina
U.S. CCO & Country Gen Manager
Sep 1, 2026Option exercise+20,000$2.35$47.00K20,000

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
9M shares short
Days to cover
4.7
At 2M shares a day
Change since last report
-4.8%
From 9M shares
Short volume, 20 days
53.6%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Autolus Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 20,803 shares on Aug 31, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Cintia Piccina
Officer
Sep 2, 20266,713$15.68KSep 2, 2026Restricted Stock Vesting
Martin Anton Pule
Officer
Sep 16, 2024698,741$2.96MSep 16, 2024Shares were issued on foundation of the company and converted from private to public shares at IPO

See a number that looks wrong?